Literature DB >> 12239065

Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).

Michael Y M Chen1, Robert E Bechtold, Paul D Savage.   

Abstract

OBJECTIVE: The purpose of this article is to illustrate the CT findings in patients with hepatic metastases from a gastrointestinal stromal tumor who were treated with STI-571.
CONCLUSION: Hepatic metastases from gastrointestinal stromal tumors that respond to treatment with STI-571 can appear as near-cystic components with well-defined borders on contrast-enhanced CT. Most metastases became smaller. These metastases resemble simple cysts, but density measurements may differentiate them from one another.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12239065     DOI： 10.2214/ajr.179.4.1791059

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  23 in total

Review 1.  [Imaging procedures for gastrointestinal stromal tumors].

Authors:  G Antoch; K Herrmann; T A Heusner; A K Buck
Journal:  Radiologe       Date:  2009-12       Impact factor: 0.635

Review 2.  Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients.

Authors:  Rodolfo Sacco; Valeria Mismas; Antonio Romano; Marco Bertini; Michele Bertoni; Graziana Federici; Salvatore Metrangolo; Giuseppe Parisi; Emanuele Tumino; Giampaolo Bresci; Luca Giacomelli; Sara Marceglia; Irene Bargellini
Journal:  World J Hepatol       Date:  2015-01-27

3.  Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.

Authors:  Christian Stroszczynski; Dominik Jost; Peter Reichardt; Petra Chmelik; Gunnar Gaffke; Albrecht Kretzschmar; Ulrike Schneider; Roland Felix; Peter Hohenberger
Journal:  Eur Radiol       Date:  2005-08-13       Impact factor: 5.315

4.  Gastrointestinal stromal tumors: CT and MRI findings.

Authors:  Kumaresan Sandrasegaran; Arumugam Rajesh; Daniel A Rushing; Jonas Rydberg; Fatih M Akisik; John D Henley
Journal:  Eur Radiol       Date:  2005-03-11       Impact factor: 5.315

5.  The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.

Authors:  G W Goerres; R Stupp; G Barghouth; T F Hany; B Pestalozzi; E Dizendorf; P Schnyder; F Luthi; G K von Schulthess; S Leyvraz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

6.  Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

Authors:  Axel Le Cesne; Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Michael Findlay; Peter Reichardt; Rolf Issels; Ian Judson; Patrick Schoffski; Serge Leyvraz; Binh Bui; Pancras C W Hogendoorn; Raf Sciot; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

Review 7.  Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.

Authors:  Gunhild Mechtersheimer; Gerlinde Egerer; Manfred Hensel; Ralf J Rieker; Martin Libicher; Thomas Lehnert; Roland Penzel
Journal:  Virchows Arch       Date:  2004-01-20       Impact factor: 4.064

8.  Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses.

Authors:  Mariacristina DI Marco; Elisa Grassi; Silvia Vecchiarelli; Sandra Durante; Marina Macchini; Guido Biasco
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

Review 9.  Utility of positron emission tomography/CT in the evaluation of small bowel pathology.

Authors:  C G Cronin; J Scott; A Kambadakone; O A Catalano; D Sahani; M A Blake; S McDermott
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

10.  Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.

Authors:  Marius Horger; Ulrich M Lauer; Christina Schraml; Christoph P Berg; Ursula Koppenhöfer; Claus D Claussen; Michael Gregor; Michael Bitzer
Journal:  BMC Cancer       Date:  2009-06-28       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.